Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non–Small-Cell Lung Cancer in the United States

Many patients with actionable driver oncogenes (ADOs) are never identified and thus never receive targeted treatment. This study evaluated the economic impact and the potential life-years gained (LYG) that can be attributed to the extent of next-generation sequencing (NGS) testing in the United Stat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemmon, Christopher A., Zhou, Jie, Hobbs, Brian, Pennell, Nathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928881/
https://www.ncbi.nlm.nih.gov/pubmed/36634300
http://dx.doi.org/10.1200/PO.22.00294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928881/
https://www.ncbi.nlm.nih.gov/pubmed/36634300
http://dx.doi.org/10.1200/PO.22.00294

Ejemplares similares